NCT00543556终止2 期
MK0767 in Type 2 Diabetes (0767-012)
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 514
研究概览
简要总结
This is a clinical trial in patients with Type 2 Diabetes to test the safety of MK0767. This study will also see how effective MK0767 is in lowering markers of glucose metabolism and improving the lipid profile and non-HDL cholesterol when compared with placebo and pioglitazone.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 21 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Type 2 Diabetes Mellitus patients between the ages of 21 and 75 inclusive
- •Patient is willing to discontinue current therapy for the duration of the study
- •Patient is not a heavy drinker
排除标准
- •Patient has a history of Type 1 diabetes and/or ketoacidosis
- •Patient has severe diabetic retinopathy, or nephropathy, or neuropath
- •Patient has has anti-hyperglycemic therapy including insulin, or rosiglitazone and pioglitazone or 2 or more oral agents in combination within 8 weeks prior to visit 1
- •Patient has a history of, allergy to, intolerance or hypersensitive to troglitazone, rosiglitazone, or pioglitazone including history of elevated liver function test, jaundice, or hepatotoxicity associated with these treatments
研究者
相似试验
终止
3 期
MK0767 and Sulfonylurea Combination Study (0767-027)Diabetes Mellitus, Type 2NCT00543491Merck Sharp & Dohme LLC129
终止
2 期
Dose-ranging Study to Evaluate the Effectiveness and Tolerability of MK0736 in Patients With Type 2 Diabetes Mellitus (T2DM) and Hypertension (0736-007)Type 2 Diabetes MellitusHypertensionNCT00806585Merck Sharp & Dohme LLC620
终止
3 期
MK0767 Added to Insulin Therapy in Patients With Type 2 Diabetes (0767-030)Diabetes Mellitus, Type 2NCT00543816Merck Sharp & Dohme LLC100
已完成
2 期
Trial of FK614 in Type 2 Diabetics Inadequately Controlled on a SulfonylureaDiabetes MellitusNCT00036192Astellas Pharma Inc200
终止
3 期
MK0767 Glipizide Comparator Cardiac Safety Study (0767-018)Diabetes Mellitus, Type 2NCT00543010Merck Sharp & Dohme LLC247